Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.71 |
| ▸ | MPO | P05164 | 11/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11050443 | 0.87 | MPO (0.61) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL30482437 | 0.84 | GPR84 (1.00) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL18383118 | 0.84 | GPR84 (1.00) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL30913603 | 0.84 | GPR84 (1.00) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL5725721 | 0.83 | GPR84 (0.63) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL31744625 | 0.82 | GPR84 (0.71) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL1993893 | 0.78 | MEN1 (0.74) | GPR84MPOHTR2AHTR1AKMT2A | |
| SCHEMBL29007187 | 0.76 | GPR84 (1.00) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL31744639 | 0.76 | GPR84 (0.71) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL7085655 | 0.76 | GPR84 (0.61) | GPR84MPOHTR2AHTR1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355900-B1 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2006-05-24 | — | — | EP | disclosed |
| CN-1492863-A | Heterocyclylalkyl-indole or azaindole compounds as 5-hydroxytryptamine-6 ligands | — | 2004-04-28 | — | — | CN | disclosed |
| US-20030225121-A1 | Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1355900-A2 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6613781-B2 | Potential use in the treatment of a variety of central nervous system disorders such as anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, congnitive disorders, sleep disorders and schizophrenia | WYETH | 2003-09-02 | — | — | US | disclosed |
| US-6610712-B2 | Treating serotonin-related central nervous system disorders | WYETH | 2003-08-26 | — | — | US | disclosed |
| US-6489342-B2 | 5-FLUORO-3-(1-(2-(1H-INDOL-4-YLOXY)ETHYL)-PIPERIDIN-4-YLMETHYL) -1H-INDOLE, FOR EXAMPLE; ACT AT THE 5-HT1A AUTORECEPTORS AND CONCOMITANTLY WITH THE 5-HT TRANSPORTER | WYETH | 2002-12-03 | — | — | US | disclosed |
| US-20020128477-A1 | Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-09-12 | — | — | US | disclosed |
| US-20020099078-A1 | Aryloxy piperidinyl indoles for treating depression | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-07-25 | — | — | US | disclosed |
| WO-2002051832-A2 | HETEROCYCLYLALKYLINDOLE OR -AZAINDOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128477-A1 | Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | GPR84 139/4885MPO 3353/4885HTR2A 5/4885 |
| US-20030225121-A1 | Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | GPR84 139/4885MPO 3353/4885HTR2A 5/4885 |
| US-20020099078-A1 | Aryloxy piperidinyl indoles for treating depression | TPH2, TPH1, HTR2C | GPR84 1786/4885MPO 1032/4885HTR2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.